新型生物制剂Ab-IPL-IL-17用于IL-17介导疾病:鉴定IL-17A/F功能的生物活性序列nIL-17
该研究首先鉴定出模拟全长蛋白促炎作用的20氨基酸IL-17A/F衍生肽nIL-17,进而生成新型抗IL-17中和单克隆抗体Ab-IPL-IL-17。在临床前小鼠模型及RA和IBD患者样本中,Ab-IPL-IL-17可有效减轻关节炎临床体征并中和IBD患者血清中升高的IL-17水平。作者结论认为Ab-IPL-IL-17具有高效力和治疗潜力,支持在IMIDs患者中开展大规模临床评估。
要点
- 鉴定出20氨基酸IL-17A/F衍生肽nIL-17,可模拟全长蛋白的促炎作用。
- Ab-IPL-IL-17能逆转nIL-17及IL-17A/F的促炎、促迁移作用。
- Ab-IPL-IL-17的脱靶效应少于当前金标准生物制剂司库奇尤单抗。
核心结论
- 临床前及体外临床证据表明Ab-IPL-IL-17具有高效力和治疗潜力,支持在IMIDs患者中开展大规模临床评估。
研究设计与样本
- 研究为临床前研究,包括体外实验、临床前小鼠模型及RA和IBD患者样本。
主要发现
- 鉴定出20氨基酸IL-17A/F衍生肽nIL-17,可模拟全长蛋白的促炎作用。
- Ab-IPL-IL-17能有效逆转nIL-17和IL-17A/F的促炎、促迁移作用。
- Ab-IPL-IL-17的脱靶效应少于当前金标准生物制剂司库奇尤单抗。
- 在临床前小鼠模型中,Ab-IPL-IL-17可有效减轻关节炎临床体征。
- Ab-IPL-IL-17可中和IBD患者血清中升高的IL-17水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Interleukin (IL) 17s cytokines are key drivers of inflammation that are functionally dysregulated in several human immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD). Targeting these cytokines has some therapeutic benefits, but issues associated with low therapeutic efficacy and immunogenicity for subgroups of patients or IMIDs reduce their clinical use. Therefore, there is an urgent need to improve the coverage and efficacy of antibodies targeting IL-17A and/or IL-17F and IL-17A/F heterodimer. METHODS AND RESULTS: Here, we initially identified a bioactive 20 amino acid IL-17A/F-derived peptide (nIL-17) that mimics the pro-inflammatory actions of the full-length proteins. Subsequently, we generated a novel anti-IL-17 neutralising monoclonal antibody (Ab-IPL-IL-17) capable of effectively reversing the pro-inflammatory, pro-migratory actions of both nIL-17 and IL-17A/F. Importantly, we demonstrated that Ab-IPL-IL-17 has less off-target effects than the current gold-standard biologic, secukinumab. Finally, we compared the therapeutic efficacy of Ab-IPL-IL-17 with reference anti-IL-17 antibodies in preclinical murine models and samples from patients with RA and IBD. We found that Ab-IPL-IL-17 could effectively reduce clinical signs of arthritis and neutralise elevated IL-17 levels in IBD patient serum. CONCLUSIONS: Collectively, our preclinical and in vitro clinical evidence indicates high efficacy and therapeutic potency of Ab-IPL-IL-17, supporting the rationale for large-scale clinical evaluation of Ab-IPL-IL-17 in patients with IMIDs.
引用
- Saviano A, Manosour AA, Raucci F, et al. New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function. Ann Rheum Dis. 2023. PMID: 37580108. doi:10.1136/ard-2023-224479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。